Unique ID issued by UMIN | UMIN000001610 |
---|---|
Receipt number | R000001937 |
Scientific Title | Gastrointestinal bleeding complicating antiplatelet treatment after percutaneous coronary intervention(PCI) |
Date of disclosure of the study information | 2009/01/05 |
Last modified on | 2011/01/03 07:22:28 |
Gastrointestinal bleeding complicating antiplatelet treatment after percutaneous coronary intervention(PCI)
Gastrointestinal bleeding complicating antiplatelet treatment after PCI
Gastrointestinal bleeding complicating antiplatelet treatment after percutaneous coronary intervention(PCI)
Gastrointestinal bleeding complicating antiplatelet treatment after PCI
Japan |
patients for indicated antiplatelet treatment after percutaneous coronary intervention(PCI)
Cardiology |
Others
NO
The current study attempted to compare the efficacy of omeprazole with omeprazole in patients indicated for antiplatelet treatment after PCI
Safety,Efficacy
Confirmatory
Explanatory
Phase IV
The current study attempted to compare the efficacy of rabeprazole with omeprazole in patients indicated for antiplatelet treatment after PCI
upper gastrointestinal bleeding.
Gastrointestinal symptom(Gastrointesitinal Symptom Rating Scale).
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
3
Treatment
Medicine |
endoscopic findings is normal and no symptom case:
they randomly divided into three treatment arms in each of the groups. Each group was randomly assigned to receive 10 mg omeprazole once a day after breakfast, 100 mg rebamipide 3 times per day after each meal, or no receiving drug during 6 months.
patients have endoscopic findings and/or symptom :
they randomly divided into two treatment arms in each of the groups. Each group was randomly assigned to receive 10 mg omeprazole once a day after breakfast, 100 mg rebamipide 3 times per day after each meal 6 months.
when patients have peptic uler, they received H. pylori eradication therapy. afer that, they receive 10 mg omeprazole once a day after breakfast.
20 | years-old | <= |
Not applicable |
Male and Female
patients indicated for antiplatelet treatment(aspirin and clopidogrel) after percutaneous coronary intervention(PCI)
Patients were excluded if patients had been malignant disease, previous upper abdominal surgery, neuropsychiatric disorder, organic brain damage, severe hepato-renal disorder, symptoms suggesting or were pregnant.
240
1st name | |
Middle name | |
Last name | Yutaka Sasaki |
Graduate School of Medicine Science, Kumamoto University
Department of Gastroenterology and Hepatology,
1-1-1 honjo, Kumamoto City, Kumamoto 860-8556, JAPAN
096-373-5150
1st name | |
Middle name | |
Last name | Kouichi Sakurai |
Graduate School of Medicine Science, Kumamoto University
Department of Gastroenterology and Hepatology,
1-1-1 honjo, Kumamoto City, Kumamoto 860-8556, JAPAN
096-373-5150(+81-96-373-5150)
Graduate School of Medicine Science, Kumamoto University
Graduate School of Medicine Science, Kumamoto University
NO
2009 | Year | 01 | Month | 05 | Day |
Unpublished
Terminated
2008 | Year | 02 | Month | 29 | Day |
2008 | Year | 09 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2011 | Year | 03 | Month | 01 | Day |
2011 | Year | 09 | Month | 01 | Day |
2012 | Year | 03 | Month | 01 | Day |
2009 | Year | 01 | Month | 01 | Day |
2011 | Year | 01 | Month | 03 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001937